Homology Medicines Inc to Announce Encouraging First Dose Level Initial Data Call Transcript
Good day and thank you for standing by, and welcome to the Homology Medicines Incorporated conference call. (Operator Instructions)
Once again, please be advised that today's conference is being recorded. I would now like to hand the conference over to Cara Mayfield, Vice President of Corporate Communications and Patient Advocacy. Please go ahead, Cara.
Thank you. And welcome to the Homology Medicines Conference Call to discuss the encouraging initial clinical data from the pheEDIT trial evaluating gene editing candidate, HMI-103, for PKU and our corporate update. This afternoon, we issued two press releases, which can be found on the Investors page of our website. Today's event is being webcasted slides. (Conference Instructions)
Before we went again, we would like to advise that as we make during this call at Homology's future expectations, plans, and prospects, including without limitation those relating to our plans to evaluate strategic options,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
